An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients
An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients
This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.001 trial
Inclusion Criteria:
Exclusion Criteria:
Gainsville, Florida, United States
Ashville, North Carolina, United States
Capital Federal, CBA, Argentina
Ciudad de Buenos Aires, Argentina
Oulun Yliopisto, Finland
Hyderabaad, India
Guadalajara - Jalisco, Mexico
Monterrey N.L., Mexico
Wellington South, New Zealand
Barrios Altos-Lima, Peru
La Victoria-Lima, Peru
San Isidro-Lima, Peru
Surco-Lima, Peru
Mures, Romania
Yaroslav, Russia
Gauteng, South Africa